Claudlo Bucolo

List of Publications by Year
in descending order

186 papers	7,494 citations	61984 43 h-index	85541 71 g-index
188 all docs	188 docs citations	188 times ranked	8760 citing authors

#	Article	IF	Citations
1	Activity-Dependent Neuroprotective Protein (ADNP)-Derived Peptide (NAP) Counteracts UV-B Radiation-Induced ROS Formation in Corneal Epithelium. Antioxidants, 2022, 11, 128.	5.1	9
2	The P2X7 receptor as a new pharmacological target for retinal diseases. Biochemical Pharmacology, 2022, 198, 114942.	4.4	12
3	Editorial: Ocular Pharmacology: Recent Breakthroughs and Unmet Needs. Frontiers in Pharmacology, 2022, 13, 848332.	3.5	1
4	Pituitary Adenylate Cyclase-Activating Polypeptide Protects Corneal Epithelial Cells against UV-B-Induced Apoptosis via ROS/JNK Pathway Inhibition. Applied Sciences (Switzerland), 2022, 12, 3435.	2.5	1
5	Efficacy and Safety of Subthreshold Micropulse Yellow Laser for Persistent Diabetic Macular Edema After Vitrectomy: A Pilot Study. Frontiers in Pharmacology, 2022, 13, 832448.	3.5	6
6	Pharmacological and Genetic Evidence of Dopamine Receptor 3-Mediated Vasoconstriction in Isolated Mouse Aorta. Biomolecules, 2021, 11, 418.	4.0	2
7	Circulating miRNAs in diabetic retinopathy patients: Prognostic markers or pharmacological targets?. Biochemical Pharmacology, 2021, 186, 114473.	4.4	19
8	Evaluation of Aqueous Flare Intensity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular Age-Related Macular Degeneration. Frontiers in Pharmacology, 2021, 12, 656774.	3.5	7
9	Epiretinal Membrane Vitrectomy With and Without Intraoperative Intravitreal Dexamethasone Implant: A Systematic Review With Meta-Analysis. Frontiers in Pharmacology, 2021, 12, 635101.	3.5	10
10	Assessment of a New Nanostructured Microemulsion System for Ocular Delivery of Sorafenib to Posterior Segment of the Eye. International Journal of Molecular Sciences, 2021, 22, 4404.	4.1	12
11	Carnosine Protects Macrophages against the Toxicity of Aî²1-42 Oligomers by Decreasing Oxidative Stress. Biomedicines, 2021, 9, 477.	3.2	27
12	Influence of Trace Elements on Neurodegenerative Diseases of The Eyeâ€"The Glaucoma Model. International Journal of Molecular Sciences, 2021, 22, 4323.	4.1	33
13	A novel arousal-based individual screening reveals susceptibility and resilience to PTSD-like phenotypes in mice. Neurobiology of Stress, 2021, 14, 100286.	4.0	42
14	Glucose-Impaired Corneal Re-Epithelialization Is Promoted by a Novel Derivate of Dimethyl Fumarate. Antioxidants, 2021, 10, 831.	5.1	6
15	Attenuation of High Glucose-Induced Damage in RPE Cells through p38 MAPK Signaling Pathway Inhibition. Frontiers in Pharmacology, 2021, 12, 684680.	3.5	22
16	Brimonidine is Neuroprotective in Animal Paradigm of Retinal Ganglion Cell Damage. Frontiers in Pharmacology, 2021, 12, 705405.	3.5	30
17	Short-and Long-Term Expression of Vegf: A Temporal Regulation of a Key Factor in Diabetic Retinopathy. Frontiers in Pharmacology, 2021, 12, 707909.	3.5	12
18	Lipid Nanoparticles Traverse Non-Corneal Path to Reach the Posterior Eye Segment: In Vivo Evidence. Molecules, 2021, 26, 4673.	3.8	17

#	Article	IF	Citations
19	1Î±,25-dihydroxyvitamin D3 protects retinal ganglion cells in glaucomatous mice. Journal of Neuroinflammation, 2021, 18, 206.	7.2	17
20	Fingolimod and Diabetic Retinopathy: A Drug Repurposing Study. Frontiers in Pharmacology, 2021, 12, 718902.	3.5	13
21	New Therapeutic Perspectives in the Treatment of Uveal Melanoma: A Systematic Review. Biomedicines, 2021, 9, 1311.	3.2	17
22	Molecular Dynamics Simulation Techniques as Tools in Drug Discovery and Pharmacology: A Focus on Allosteric Drugs. Methods in Molecular Biology, 2021, 2253, 245-254.	0.9	13
23	Targeting the miRNA-155/TNFSF10 network restrains inflammatory response in the retina in a mouse model of Alzheimerâ€™s disease. Cell Death and Disease, 2021, 12, 905.	6.3	16
24	Effects of Vitamin D3 and Meso-Zeaxanthin on Human Retinal Pigmented Epithelial Cells in Three Integrated in vitro Paradigms of Age-Related Macular Degeneration. Frontiers in Pharmacology, 2021, 12, 778165.	3.5	7
25	Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice. Frontiers in Pharmacology, 2021, 12, 720345.	3.5	18
26	Do Extracellular RNAs Provide Insight into Uveal Melanoma Biology?. Cancers, 2021, 13, 5919.	3.7	6
27	Caffeine Protects Against Retinal Inflammation. Frontiers in Pharmacology, 2021, 12, 824885.	3.5	10
28	Activation of the VEGF-A/ERK/PLA2 Axis Mediates Early Retinal Endothelial Cell Damage Induced by High Glucose: New Insight from an In Vitro Model of Diabetic Retinopathy. International Journal of Molecular Sciences, 2020, 21, 7528.	4.1	35
29	The immune system on the TRAIL of Alzheimerâ€™s disease. Journal of Neuroinflammation, 2020, 17, 298.	7.2	42
30	Stabilization of HIF-1Î± in Human Retinal Endothelial Cells Modulates Expression of miRNAs and Proangiogenic Growth Factors. Frontiers in Pharmacology, 2020, 11, 1063.	3.5	32
31	TGF-Î² Serum Levels in Diabetic Retinopathy Patients and the Role of Anti-VEGF Therapy. International Journal of Molecular Sciences, 2020, 21, 9558.	4.1	35
32	Novel Heme Oxygenase-1 (HO-1) Inducers Based on Dimethyl Fumarate Structure. International Journal of Molecular Sciences, 2020, 21, 9541.	4.1	9
33	Case Report: Central Retinal Artery Occlusion in a COVID-19 Patient. Frontiers in Pharmacology, 2020, 11, 588384.	3.5	72
34	Multidisciplinary Approach to the Diagnosis and In-Hospital Management of COVID-19 Infection: A Narrative Review. Frontiers in Pharmacology, 2020, 11, 572168.	3.5	17
35	Dihydrotanshinone, a Natural Diterpenoid, Preserves Blood-Retinal Barrier Integrity via P2X7 Receptor. International Journal of Molecular Sciences, 2020, 21, 9305.	4.1	17
36	P2X7 receptor antagonism preserves retinal ganglion cells in glaucomatous mice. Biochemical Pharmacology, 2020, 180, 114199.	4.4	34

#	Article	IF	Citations
37	Resolvin D1 attenuates the inflammatory process in mouse model of LPSâ€induced keratitis. Journal of Cellular and Molecular Medicine, 2020, 24, 12298-12307.	3.6	12
38	New Brilliant Blue G Derivative as Pharmacological Tool in Retinal Surgery. Frontiers in Pharmacology, 2020, 11, 708.	3.5	8
39	Retinal biomarkers and pharmacological targets for Hermansky-Pudlak syndrome 7. Scientific Reports, 2020, 10, 3972.	3.3	7
40	Resolvin D1 Modulates the Intracellular VEGF-Related miRNAs of Retinal Photoreceptors Challenged With High Glucose. Frontiers in Pharmacology, 2020, 11, 235.	3.5	33
41	A New Human Bloodâ€"Retinal Barrier Model Based on Endothelial Cells, Pericytes, and Astrocytes. International Journal of Molecular Sciences, 2020, 21, 1636.	4.1	54
42	Effects of protein-protein interface disruptors at the ligand of the glucocorticoid-induced tumor necrosis factor receptor-related gene (GITR). Biochemical Pharmacology, 2020, 178, 114110.	4.4	9
43	Ocular Formulation Based on Palmitoylethanolamide-Loaded Nanostructured Lipid Carriers: Technological and Pharmacological Profile. Nanomaterials, 2020, 10, 287.	4.1	32
44	Modulation of Pro-Oxidant and Pro-Inflammatory Activities of M1 Macrophages by the Natural Dipeptide Carnosine. International Journal of Molecular Sciences, 2020, 21, 776.	4.1	77
45	Novel indole derivatives targeting HuR-mRNA complex to counteract high glucose damage in retinal endothelial cells. Biochemical Pharmacology, 2020, 175, 113908.	4.4	27
46	Pain Following the Use of Anesthesia Formulation Among Individuals Undergoing Cataract Surgery: A Randomized Controlled Trial. Frontiers in Pharmacology, 2020, 11, 440.	3.5	8
47	Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment. Biochemical Pharmacology, 2020, 177, 114004.	4.4	36
48	MicroRNAs in the Vitreous Humor of Patients with Retinal Detachment and a Different Grading of Proliferative Vitreoretinopathy: A Pilot Study. Translational Vision Science and Technology, 2020, 9, 23.	2.2	30
49	Comparative Safety of Bevacizumab, Ranibizumab, and Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Network Meta-Analysis of Direct Comparative Studies. Journal of Clinical Medicine, 2020, 9, 1522.	2.4	52
50	Pericyte-like differentiation of human adipose-derived mesenchymal stem cells: An in vitro study. World Journal of Stem Cells, 2020, 12, 1152-1170.	2.8	25
51	Carnosine Decreases PMA-Induced Oxidative Stress and Inflammation in Murine Macrophages. Antioxidants, 2019, 8, 281.	5.1	56
52	Dopamine outside the brain: The eye, cardiovascular system and endocrine pancreas. , 2019, 203, 107392.		86
53	Blood-retinal barrier protection against high glucose damage: The role of P2X7 receptor. Biochemical Pharmacology, 2019, 168, 249-258.	4.4	39
54	Aflibercept regulates retinal inflammation elicited by high glucose via the PlGF/ERK pathway. Biochemical Pharmacology, 2019, 168, 341-351.	4.4	57

#	Article	IF	Citations
55	Ocular Pharmacological Profile of Hydrocortisone in Dry Eye Disease. Frontiers in Pharmacology, 2019, 10, 1240.	3.5	27
56	Dopaminergic-GABAergic interplay and alcohol binge drinking. Pharmacological Research, 2019, 141, 384-391.	7.1	18
57	The activation of retinal HCA2 receptors by systemic beta-hydroxybutyrate inhibits diabetic retinal damage through reduction of endoplasmic reticulum stress and the NLRP3 inflammasome. PLoS ONE, 2019, 14, e0211005.	2.5	44
58	Protective effect of PACAP-38 on retinal pigmented epithelium in an in vitro and in vivo model of diabetic retinopathy through EGFR-dependent mechanism. Peptides, 2019, 119, 170108.	2.4	33
59	Novel ophthalmic formulation of myriocin: implications in retinitis pigmentosa. Drug Delivery, 2019, 26, 237-243.	5.7	28
60	Retinal and circulating mi<scp>RNA</scp> expression patterns in diabetic retinopathy: An in silico and in vivo approach. British Journal of Pharmacology, 2019, 176, 2179-2194.	5.4	104
61	Prognostic significance of deregulated microRNAs in uveal melanomas. Molecular Medicine Reports, 2019, 19, 2599-2610.	2.4	69
62	LATE-ONSET OCULAR HYPERTENSION AFTER VITRECTOMY. Retina, 2019, 39, 2107-2115.	1.7	6
63	Curcumin prevents high glucose damage in retinal pigment epithelial cells through ERK1/2â€mediated activation of the Nrf2/HOâ€1 pathway. Journal of Cellular Physiology, 2019, 234, 17295-17304.	4.1	65
64	Synthesis, in vitro and in silico studies of HO-1 inducers and lung antifibrotic agents. Future Medicinal Chemistry, 2019, 11, 1523-1536.	2.3	13
65	NAP modulates hyperglycemicâ€“inflammatory event of diabetic retina by counteracting outer blood retinal barrier damage. Journal of Cellular Physiology, 2019, 234, 5230-5240.	4.1	20
66	Isolation, cultivation, and characterization of primary bovine cochlear pericytes: A new in vitro model of stria vascularis. Journal of Cellular Physiology, 2019, 234, 1978-1986.	4.1	10
67	Therapeutic Potential of Nitric Oxide Modulation in Ocular Diseases: A Focus on Novel NO-Releasing Molecules. , 2019, , 333-334.		0
68	POOLED ESTIMATES OF INCIDENCE OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION OF ANTIâ€“VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS WITH AND WITHOUT TOPICAL ANTIBIOTIC PROPHYLAXIS. Retina, 2018, 38, 01-11.	1.7	37
69	Antioxidant and Osmoprotecting Activity of Taurine in Dry Eye Models. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 188-194.	1.4	30
70	Long-term efficacy and safety profile of multiple injections of intravitreal dexamethasone implant to manage diabetic macular edema: A systematic review of real-world studies. Journal of Pharmacological Sciences, 2018, 138, 219-232.	2.5	74
71	Computational systems biology approach to identify novel pharmacological targets for diabetic retinopathy. Biochemical Pharmacology, 2018, 158, 13-26.	4.4	43
72	Innovative Nanoparticles Enhance N-Palmitoylethanolamide Intraocular Delivery. Frontiers in Pharmacology, 2018, 9, 285.	3.5	35

#	Article	IF	Citations
73	Retinal Protection and Distribution of Curcumin in Vitro and in Vivo. Frontiers in Pharmacology, 2018, 9, 670.	3.5	34
74	Novel Therapeutics in Glaucoma Management. Current Neuropharmacology, 2018, 16, 978-992.	2.9	37
75	Nap Interferes with Hypoxia-Inducible Factors and VEGF Expression in Retina of Diabetic Rats. Journal of Molecular Neuroscience, 2017, 61, 256-266.	2.3	35
76	Modulation of IL-1Î² and VEGF expression in rat diabetic retinopathy after PACAP administration. Peptides, 2017, 97, 64-69.	2.4	33
77	Sulodexide prevents activation of the PLA2/COX-2/VEGF inflammatory pathway in human retinal endothelial cells by blocking the effect of AGE/RAGE. Biochemical Pharmacology, 2017, 142, 145-154.	4.4	42
78	Topical Ocular Delivery of TGF-Î²1 to the Back of the Eye: Implications in Age-Related Neurodegenerative Diseases. International Journal of Molecular Sciences, 2017, 18, 2076.	4.1	34
79	Retinal and Circulating miRNAs in Age-Related Macular Degeneration: An In vivo Animal and Human Study. Frontiers in Pharmacology, 2017, 8, 168.	3.5	90
80	Gabapentin Attenuates Ocular Inflammation: In vitro and In vivo Studies. Frontiers in Pharmacology, 2017, 8, 173.	3.5	29
81	Apixaban Enhances Vasodilatation Mediated by Protease-Activated Receptor 2 in Isolated Rat Arteries. Frontiers in Pharmacology, 2017, 8, 480.	3.5	17
82	Buspirone Counteracts MK-801-Induced Schizophrenia-Like Phenotypes through Dopamine D3 Receptor Blockade. Frontiers in Pharmacology, 2017, 8, 710.	3.5	24
83	Effects of Novel Nitric Oxide-Releasing Molecules against Oxidative Stress on Retinal Pigmented Epithelial Cells. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-11.	4.0	37
84	P2X7 receptor antagonism: Implications in diabetic retinopathy. Biochemical Pharmacology, 2017, 138, 130-139.	4.4	71
85	Ocular pharmacology: Cinderella becomes the queen. European Journal of Pharmacology, 2016, 787, 1.	3.5	0
86	Nanosystems based on siRNA silencing HuR expression counteract diabetic retinopathy in rat. Pharmacological Research, 2016, 111, 713-720.	7.1	84
87	Current drug treatments targeting dopamine D3 receptor. , 2016, 165, 164-177.		87
88	The antineoplastic drug flavopiridol reverses memory impairment induced by Amyloid-ÃŸ 1-42 oligomers in mice. Pharmacological Research, 2016, 106, 10-20.	7.1	32
89	TGF-Î²1 prevents rat retinal insult induced by amyloid-Î² (1â€“42) oligomers. European Journal of Pharmacology, 2016, 787, 72-77.	3.5	39
90	Folate status in type 2 diabetic patients with and without retinopathy. Clinical Ophthalmology, 2015, 9, 1437.	1.8	37

#	Article	IF	Citations
91	Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach. Frontiers in Pharmacology, 2015, 6, 248.	3.5	73
92	Effects of Topical Fucosyl-Lactose, a Milk Oligosaccharide, on Dry Eye Model: An Example of Nutraceutical Candidate. Frontiers in Pharmacology, 2015, 6, 280.	3.5	18
93	Effects of novel hybrids of caffeic acid phenethyl ester and NSAIDs on experimental ocular inflammation. European Journal of Pharmacology, 2015, 752, 78-83.	3.5	20
94	Different Retinal Expression Patterns of IL-1Î±, IL-1Î², and Their Receptors in a Rat Model of Type 1 STZ-Induced Diabetes. Journal of Molecular Neuroscience, 2015, 56, 431-439.	2.3	36
95	MicroRNA target prediction in glaucoma. Progress in Brain Research, 2015, 220, 217-240.	1.4	40
96	Intravitreal Triamcinolone Acetonide in the Treatment of Ophthalmic Inflammatory Diseases with Macular Edema: A Meta-Analysis Study. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 228-240.	1.4	7
97	Nrf2 activators modulate oxidative stress responses and bioenergetic profiles of human retinal epithelial cells cultured in normal or high glucose conditions. Pharmacological Research, 2015, 99, 296-307.	7.1	65
98	Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2/COX-2/VEGF-A pathway. Biochemical Pharmacology, 2015, 96, 278-287.	4.4	63
99	Dopamine D3 receptor-dependent changes in alpha6 GABAA subunit expression in striatum modulate anxiety-like behaviour: Responsiveness and tolerance to diazepam. European Neuropsychopharmacology, 2015, 25, 1427-1436.	0.7	28
100	PACAP Modulates Expression of Hypoxia-Inducible Factors in Streptozotocin-Induced Diabetic Rat Retina. Journal of Molecular Neuroscience, 2015, 57, 501-509.	2.3	55
101	Cationic solid lipid nanoparticles enhance ocular hypotensive effect of melatonin in rabbit. International Journal of Pharmaceutics, 2015, 478, 180-186.	5.2	71
102	Controversies in Glaucoma: Current Medical Treatment and Drug Development. Current Pharmaceutical Design, 2015, 21, 4673-4681.	1.9	32
103	Role of Omega-3 Fatty Acids in the Treatment of Depressive Disorders: A Comprehensive Meta-Analysis of Randomized Clinical Trials. PLoS ONE, 2014, 9, e96905.	2.5	358
104	Omega-3 Fatty Acids and Depression: Scientific Evidence and Biological Mechanisms. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-16.	4.0	215
105	Dopamine D3 Receptor Is Necessary for Ethanol Consumption: An Approach with Buspirone. Neuropsychopharmacology, 2014, 39, 2017-2028.	5.4	52
106	Homocysteine Serum Levels in Diabetic Patients with Non Proliferative, Proliferative and without Retinopathy. BioMed Research International, 2014, 2014, 1-4.	1.9	40
107	Regulation of vascular tone in rabbit ophthalmic artery: Cross talk of endogenous and exogenous gas mediators. Biochemical Pharmacology, 2014, 92, 661-668.	4.4	26
108	Davunetide (NAP) Protects the Retina Against Early Diabetic Injury by Reducing Apoptotic Death. Journal of Molecular Neuroscience, 2014, 54, 395-404.	2.3	31

#	Article	IF	Citations
109	Low levels of 17-Î²-oestradiol, oestrone and testosterone correlate with severe evaporative dysfunctional tear syndrome in postmenopausal women: a caseâ€“control study. British Journal of Ophthalmology, 2014, 98, 371-376.	3.9	58
110	Influence of different surfactants on the technological properties and in vivo ocular tolerability of lipid nanoparticles. International Journal of Pharmaceutics, 2014, 470, 133-140.	5.2	72
111	Effects of topical indomethacin, bromfenac and nepafenac on lipopolysaccharide-induced ocular inflammationâ€. Journal of Pharmacy and Pharmacology, 2014, 66, 954-960.	2.4	25
112	Dopamine D3 receptor as a new pharmacological target for the treatment of depression. European Journal of Pharmacology, 2013, 719, 25-33.	3.5	115
113	Reversible inhibition of vasoconstriction by thiazolidinediones related to PI3K/Akt inhibition in vascular smooth muscle cells. Biochemical Pharmacology, 2013, 85, 551-559.	4.4	16
114	Small molecule activators of the Nrf2-HO-1 antioxidant axis modulate heme metabolism and inflammation in BV2 microglia cells. Pharmacological Research, 2013, 76, 132-148.	7.1	150
115	Regulation of intraocular pressure in mice: Structural analysis of dopaminergic and serotonergic systems in response to cabergoline. Biochemical Pharmacology, 2013, 86, 1347-1356.	4.4	16
116	Metal fume fever. Lancet, The, 2013, 381, 2298.	13.7	7
117	Role of phospholipases A2 in diabetic retinopathy: In vitro and in vivo studies. Biochemical Pharmacology, 2013, 86, 1603-1613.	4.4	67
118	Polymeric nanoparticles augment the ocular hypotensive effect of melatonin in rabbits. International Journal of Pharmaceutics, 2013, 440, 135-140.	5.2	89
119	Pharmacological management of ocular hypertension: current approaches and future prospective. Current Opinion in Pharmacology, 2013, 13, 50-55.	3.5	66
120	Behavioural and neurochemical changes induced by stress-related conditions are counteracted by the neurokinin-2 receptor antagonist saredutant. International Journal of Neuropsychopharmacology, 2013, 16, 813-823.	2.1	14
121	Lipoprotein(a) Serum Levels in Diabetic Patients with Retinopathy. BioMed Research International, 2013, 2013, 1-5.	1.9	23
122	Fortified Extract of Red Berry,Ginkgo biloba, and White Willow Bark in Experimental Early Diabetic Retinopathy. Journal of Diabetes Research, 2013, 2013, 1-6.	2.3	39
123	Ocular drug delivery: a clue from nanotechnology. Frontiers in Pharmacology, 2012, 3, 188.	3.5	94
124	Safety profile assessment of buflomedil: an overview of adverse reactions between 1975 and 2011. Pharmacoepidemiology and Drug Safety, 2012, 21, 1190-1196.	1.9	6
125	Early changes in pituitary adenylate cyclase-activating peptide, vasoactive intestinal peptide and related receptors expression in retina of streptozotocin-induced diabetic rats. Peptides, 2012, 37, 32-39.	2.4	59
126	Potential drug mechanism(s) targeting the contractile status of hepatic stellate cells. Frontiers in Pharmacology, 2012, 3, 187.	3.5	0

#	Article	IF	Citations
127	Dopamine-3 receptor modulates intraocular pressure: Implications for glaucoma. Biochemical Pharmacology, 2012, 83, 680-686.	4.4	28
128	Eriodictyol prevents early retinal and plasma abnormalities in streptozotocin-induced diabetic rats. Biochemical Pharmacology, 2012, 84, 88-92.	4.4	126
129	Eriodictyol prevents early retinal and plasma abnormalities in streptozotocin-induced diabetic rats. , 2012, 84, 88-88.		1
130	Homology Modeling of Dopamine D2 and D3 Receptors: Molecular Dynamics Refinement and Docking Evaluation. PLoS ONE, 2012, 7, e44316.	2.5	62
131	Acidic Mammalian Chitinase and the Eye: Implications for Ocular Inflammatory Diseases. Frontiers in Pharmacology, 2011, 2, 43.	3.5	26
132	In Vivo Ocular Efficacy Profile of Mapracorat, a Novel Selective Glucocorticoid Receptor Agonist, in Rabbit Models of Ocular Disease. , 2011, 52, 1422.		57
133	Effect of Sodium Naproxen on Inflammatory Response Induced by Anterior Chamber Paracentesis in the Rabbit. Journal of Pharmacy and Pharmacology, 2011, 47, 708-712.	2.4	8
134	Carbon monoxide and the eye: Implications for glaucoma therapy. , 2011, 130, 191-201.		52
135	Ocular Pharmacokinetics Profile of Different Indomethacin Topical Formulations. Journal of Ocular Pharmacology and Therapeutics, 2011, 27, 571-576.	1.4	23
136	Eosinophil as a cellular target of the ocular anti-allergic action of mapracorat, a novel selective glucocorticoid receptor agonist. Molecular Vision, 2011, 17, 3208-23.	1.1	18
137	Eudragit RL100 nanoparticle system for the ophthalmic delivery of cloricromene. Journal of Pharmacy and Pharmacology, 2010, 56, 841-846.	2.4	49
138	Characterization and In-vivo Ocular Absorption of Liposome-encapsulated Acyclovir. Journal of Pharmacy and Pharmacology, 2010, 51, 565-576.	2.4	49
139	New coumarin-based anti-inflammatory drug: putative antagonist of the integrins Î±LÎ²2 and Î±MÎ²2. Journal of Pharmacy and Pharmacology, 2010, 60, 1473-1479.	2.4	6
140	Morphine-Induced Ocular Hypotension Is Modulated by Nitric Oxide and Carbon Monoxide: Role of Î¼₃Receptors. Journal of Ocular Pharmacology and Therapeutics, 2010, 26, 31-36.	1.4	18
141	The PKCÎ²/HuR/VEGF pathway in diabetic retinopathy. Biochemical Pharmacology, 2010, 80, 1230-1237.	4.4	95
142	Therapeutic potential of nitric oxide modulation in ocular diseases. Drug News and Perspectives, 2010, 23, 430.	1.5	15
143	Protective Effects of a Coumarin Derivative in Diabetic Rats. , 2009, 50, 3846.		56
144	Focus on molecules: Heme oxygenase-1. Experimental Eye Research, 2009, 89, 822-823.	2.6	10

#	Article	IF	Citations
145	Acidic Mammalian Chitinase in Dry Eye Conditions. Cornea, 2009, 28, 667-672.	1.7	34
146	Contribution of Î±4Î²1 integrin to the antiallergic effect of levocabastine. Biochemical Pharmacology, 2008, 76, 751-762.	4.4	33
147	Effect of chitinase inhibitors on endotoxin-induced uveitis (EIU) in rabbits. Pharmacological Research, 2008, 57, 247-252.	7.1	34
148	When nanotechnology meets the ocular surface. Expert Review of Ophthalmology, 2008, 3, 325-332.	0.6	34
149	Chitinase Levels in the Tears of Subjects With Ocular Allergies. Cornea, 2008, 27, 168-173.	1.7	38
150	Retinal and Systemic Pharmacokinetics of the Anti-Inflammatory Drug Cloricromene Following Oral Administration in the Rat and Rabbit. Journal of Ocular Pharmacology and Therapeutics, 2007, 23, 257-263.	1.4	0
151	Protective effects of the sigma agonist Pre-084 in the rat retina. British Journal of Ophthalmology, 2007, 91, 1382-1384.	3.9	29
152	Hemin, an Inducer of Heme Oxygenase-1, Lowers Intraocular Pressure in Rabbits. Journal of Ocular Pharmacology and Therapeutics, 2007, 23, 232-239.	1.4	14
153	Hydroxyl Radical Scavenging Activity of a New Ophthalmic Viscosurgical Device. Current Eye Research, 2007, 32, 105-111.	1.5	11
154	Development and validation of an RP-HPLC-UV method for the determination of BOL-303225-A, a new coumarin-based anti-inflammatory drug, in rat plasma. Biomedical Chromatography, 2007, 21, 351-355.	1.7	6
155	Neuroactive Steroids Protect Retinal Tissue through ?1Receptors. Basic and Clinical Pharmacology and Toxicology, 2007, 100, 214-216.	2.5	8
156	Sigma receptor ligands protect human retinal cells against oxidative stress. NeuroReport, 2006, 17, 287-291.	1.2	54
157	Preparation and characterization of Eudragit Retard nanosuspensions for the ocular delivery of cloricromene. AAPS PharmSciTech, 2006, 7, E192-E198.	3.3	87
158	Novel polysaccharides-based viscoelastic formulations for ophthalmic surgery: Rheological characterization. Biomaterials, 2006, 27, 5134-5142.	11.4	56
159	Possible involvement of nitric oxide in morphine-induced miosis and reduction of intraocular pressure in rabbits. European Journal of Pharmacology, 2006, 534, 227-232.	3.5	18
160	A novel adamantane derivative attenuates retinal ischemiaâ€“reperfusion damage in the rat retina through Ïƒ1 receptors. European Journal of Pharmacology, 2006, 536, 200-203.	3.5	20
161	Neuroactive steroids protect retinal pigment epithelium against oxidative stress. NeuroReport, 2005, 16, 1203-1207.	1.2	18
162	Simple determination of riluzole in rat brain by high-performance liquid chromatography and spectrophotometric detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 817, 331-334.	2.3	24

#	Article	IF	Citations
163	Systemic Omega-6 Essential Fatty Acid Treatment and PGE₁Tear Content in Sjoˆgrenâ€™s Syndrome Patients. , 2005, 46, 4474.		115
164	Hyaluronan-Induced Stimulation of Corneal Wound Healing is a Pure Pharmacological Effect. Journal of Ocular Pharmacology and Therapeutics, 2004, 20, 548-553.	1.4	42
165	Effects of neurosteroids on ischemiaâ€“reperfusion injury in the rat retina: role of Ïƒ1 recognition sites. European Journal of Pharmacology, 2004, 498, 111-114.	3.5	47
166	Rapid determination of nimesulide in rabbit aqueous humor by liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 804, 441-443.	2.3	26
167	Effects of Hyaluronan on Free-Radical Formation, Corneal Endothelium Damage, and Inflammation Parameters After Phacoemulsification in Rabbits. Journal of Ocular Pharmacology and Therapeutics, 2004, 20, 151-157.	1.4	18
168	Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability. Pharmaceutical Research, 2003, 20, 584-590.	3.5	149
169	Topical Application of a Nitric Oxide Synthase Inhibitor Reduces Intraocular Pressure in Rabbits with Experimental Glaucoma. Journal of Ocular Pharmacology and Therapeutics, 2003, 19, 527-534.	1.4	30
170	Effects of Cloricromene, a Coumarin Derivative, on Endotoxin-Induced Uveitis in Lewis Rats. , 2003, 44, 1178.		24
171	Pharmacological Profile of Oxaprozin Eye Drops. Journal of Ocular Pharmacology and Therapeutics, 2002, 18, 75-81.	1.4	2
172	Enhanced Ocular Anti-Inflammatory Activity of Ibuprofen Carried by an Eudragit RS100^{Â®} Nanoparticle Suspension. Ophthalmic Research, 2002, 34, 319-323.	1.9	75
173	Ocular Hypotensive Action of Topical Flunarizine in the Rabbit: Role of Ï‚1 Recognition Sites. Journal of Pharmacology and Experimental Therapeutics, 2002, 303, 1086-1094.	2.5	28
174	Eudragit RS100Â® nanosuspensions for the ophthalmic controlled delivery of ibuprofen. European Journal of Pharmaceutical Sciences, 2002, 16, 53-61.	4.0	298
175	Ocular Tolerability of Eudragit RS100Â® and RL100Â® Nanosuspensions as Carriers for Ophthalmic Controlled Drug Delivery. Journal of Pharmaceutical Sciences, 2002, 91, 2636-2641.	3.3	80
176	Rapid high-performance liquid chromatographic assay of dorzolamide in rabbit aqueous humor. Biomedical Chromatography, 2002, 16, 274-276.	1.7	10
177	Simultaneous determination of cloricromene and its active metabolite in rabbit aqueous humor by high-performance liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 767, 153-158.	2.3	5
178	Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials, 2002, 23, 3247-3255.	11.4	231
179	Ocular Surface Changes in Type 1 Diabetic Patients. Advances in Experimental Medicine and Biology, 2002, 506, 667-672.	1.6	13
180	Biocompatibility and biodegradation of intravitreal hyaluronan implants in rabbits. Biomaterials, 2001, 22, 195-200.	11.4	63

#	Article	IF	Citations
181	Ocular Tolerability and In Vivo Bioavailability of Poly(ethylene glycol) (PEG)â€Coated Polyethylâ€2â€Cyanoacrylate Nanosphereâ€Encapsulated Acyclovir. Journal of Pharmaceutical Sciences, 2001, 90, 288-297.	3.3	84
182	Pharmacological Evaluation of a New Timolol/Pilocarpine Formulation. Ophthalmic Research, 1998, 30, 101-106.	1.9	9
183	Pharmacological Evaluation of Anti-Inflammatory Pyrrole-Acetic Acid Derivative Eye Drops. Journal of Ocular Pharmacology and Therapeutics, 1997, 13, 353-361.	1.4	8
184	Effects of MipragosideÂ® on Ocular Allergic Inflammation in the Rabbit. Journal of Ocular Pharmacology and Therapeutics, 1993, 9, 321-332.	1.4	3
185	Effects of Sodium Naproxen Eye Drops on Rabbit Ocular Inflammation Induced by Sodium Arachidonate. Journal of Ocular Pharmacology and Therapeutics, 1991, 7, 125-133.	1.4	23
186	Editorial: Chronic Inflammation and Neurodegeneration in Retinal Disease, Volume II. Frontiers in Pharmacology, 0, 13, .	3.5	1